Determination and validation of cefadroxil, ceftriaxone and cefotaxime by using n-bromosuccinamide in human plasma and pharmaceutical dosage form

Aswani Kumar CH (1) , Gurupadayya BM (2) , Navya Sloka S (3)
(1) Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS University, Mysore 570 015, Karnataka, India, India ,
(2) Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS University, Mysore 570 015, Karnataka, India, India ,
(3) Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS University, Mysore 570 015, Karnataka, India, India

Abstract

Selective and highly sensitive spectrophotometric method was developed for the determination of three cephalosporins, namely cefadroxil, ceftriaxone and cefotaxime. Spectrophotometric method involves adding a measured excess of NBS to the drugs in acid medium followed by determination of residual NBS by reacting with a fixed amount of methyl orange and measuring the absorbance at 508nm. The measured absorbance is found to increase linearly with the concentration of cephalosporins serving as basis for quantitation. Under the described conditions, the proposed method is linear over the concentration range of 2.0-6.0 µg/ml, 1.5-4.5 µg/ml and 1.2-3.2 µg/ml for cefadroxil, ceftriaxone and cefotaxime respectively and the coefficients of variation was found to be in the range of 0.9992-0.9997. The recoveries of the title compounds in spiked plasma and in pharmaceutical dosage form ranged from 83.0 to 118.0% with a limit of detection (LOD) in the range of 0.0240- 0.088 µg/ml and limit of quantification in the range of 0.0720-0.264 µg/ml (LOQ) of for all the three drugs.

Full text article

Generated from XML file

Authors

Aswani Kumar CH
Gurupadayya BM
bm_guru2004@yahoo.co.in (Primary Contact)
Navya Sloka S
Aswani Kumar CH, Gurupadayya BM, & Navya Sloka S. (2011). Determination and validation of cefadroxil, ceftriaxone and cefotaxime by using n-bromosuccinamide in human plasma and pharmaceutical dosage form. International Journal of Research in Pharmaceutical Sciences, 2(2), 206–212. Retrieved from https://ijrps.com/home/article/view/3125

Article Details

No Related Submission Found